Explore baxter.com

This global site is intended for Healthcare Professionals only. All products may not be available in all countries. Contact your local Baxter representative

Renal Care

Therapies

We deliver and support renal therapies across the continuum of care, including the innovative HDx.

Therapies
  • Acute Therapy

    Organ support and blood purification therapies are essential to improving patient outcomes in the ICU.

  • Peritoneal Dialysis

    Peritoneal Dialysis - combined with Remote Patient Management - offers the potential to improve renal patients' clinical outcomes and increase lifestyle flexibility.

  • Hemodialysis

    Hemodialysis is the predominant therapy for end-stage kidney disease, and can be delivered through multiple therapy options.

  • HDx Therapy

    HDx - also known as expanded hemodialysis - is an innovative therapy that effectively targets the removal of large middle molecules.

Products

Learn more about Baxter’s key products for Renal Care – across the continuum of care.

Data & Insights

Groundbreaking research and inspirational patient stories.

  • Clinical Data

    Explore the research enabling innovative Renal Care.

  • Stories

    Patients’ journeys inspire our work and drive our commitment.

  • Resource Library

    Access resources for Baxter’s broader Renal Care portfolio.

Changes in plasma sclerostin level associated with use of a medium cut-off dialyzer in end-stage renal disease.

Learn More
  • Greater reduction ratio in MCO than in control for several larger middle molecules: growth differentiation factor 15 (GDF15) 62.6% vs 35.7% (p<0.001); sclerostin 52.6% vs 31.6% (p < 0.001); FGF23 47.8% vs 18.9% (p = 0.005); RBP4 24.4% vs 7.2% (p = 0.005). Significant difference between the two groups in change of plasma sclerostin over 12 months (adjusted mean difference: -1,647 pg/ml, p = 0.021).